Trials / Withdrawn
WithdrawnNCT01576887
A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multi-center, double-blinded, randomized, study of bardoxolone methyl treatment in patients with End-Stage Renal Disease (ERSD) and Type 2 Diabetes Mellitus (T2DM) on peritoneal dialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bardoxolone Methyl 20 mg | Oral, once daily |
| DRUG | Placebo | Oral, once daily |
Timeline
- Start date
- 2012-07-31
- Primary completion
- 2012-10-31
- Completion
- 2012-10-31
- First posted
- 2012-04-13
- Last updated
- 2025-05-29
Source: ClinicalTrials.gov record NCT01576887. Inclusion in this directory is not an endorsement.